<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255814</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0438</org_study_id>
    <secondary_id>CDR0000450766</secondary_id>
    <nct_id>NCT00255814</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Liver Metastases</brief_title>
  <official_title>A Phase I Trial of Highly Conformal Radiation Therapy for Patients With Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to&#xD;
      the tumor may kill more tumor cells and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy&#xD;
      in treating patients with liver metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of high dose per fraction, highly conformal&#xD;
           radiotherapy in patients with liver metastases.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the failure patterns and survival of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate dose-volume characteristics with possible toxic effects of this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the local control rate within irradiated fields in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients undergo highly conformal radiotherapy (HCR) to the liver once daily, 5 days a week,&#xD;
      for 2 weeks.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of HCR until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximally tolerated dose</measure>
    <time_frame>From start of treatment to 90 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy dose level II: 4.0 Gy/fx</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiation therapy dose level II: 4.0 Gy/fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy dose level III: 4.5 Gy/fx</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiation therapy dose level III: 4.5 Gy/fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy dose level IV: 5.0 Gy/fx</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiation therapy dose level IV: 5.0 Gy/fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Radiation therapy dose level II: 4.0 Gy/fx</arm_group_label>
    <arm_group_label>Radiation therapy dose level III: 4.5 Gy/fx</arm_group_label>
    <arm_group_label>Radiation therapy dose level IV: 5.0 Gy/fx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically confirmed non-lymphoma liver metastases&#xD;
&#xD;
               -  New radiographic liver lesions most consistent with metastases in a patient with&#xD;
                  known, histologically proven non-lymphoma cancer AND a previously negative CT&#xD;
                  scan, MRI, or PET/CT scan of the liver&#xD;
&#xD;
          -  No more than 5 measurable lesions by contrast-enhanced liver CT scan, MRI, or PET/CT&#xD;
             scan&#xD;
&#xD;
          -  Liver metastases ≤ 8 cm&#xD;
&#xD;
          -  Medically unfit for surgery OR lesions are surgically unresectable&#xD;
&#xD;
          -  All intrahepatic disease must be encompassed within the study radiation field&#xD;
&#xD;
          -  Extrahepatic disease outside the liver is allowed provided the hepatic disease is&#xD;
             life-limiting&#xD;
&#xD;
          -  At least 1,000 cc of normal liver&#xD;
&#xD;
          -  No clinical ascites&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,800/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No active hepatitis&#xD;
&#xD;
          -  No clinically significant liver failure&#xD;
&#xD;
          -  No underlying cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure requiring hospitalization within the past 6 months&#xD;
&#xD;
          -  No unstable angina pectoris requiring hospitalization within the past 6 months&#xD;
&#xD;
          -  No transmural myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
             requiring hospitalization or precluding study therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 3 years except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the breast, oral cavity, cervix or primary liver metastasis&#xD;
&#xD;
          -  No acute bacterial or fungal infection requiring IV antibiotics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No anthracyclines within 4 weeks after completion of study therapy (1 week for other&#xD;
             chemotherapy)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the region of study&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior liver resection or ablative therapy allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent warfarin or IV heparin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan W. Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura A. Dawson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>November 14, 2015</last_update_submitted>
  <last_update_submitted_qc>November 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

